New insider activity at Johnson & Johnson ( (JNJ) ) has taken place on October 20, 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
John C. Reed, the Executive Vice President of Innovative Medicine and R&D at Johnson & Johnson, has recently sold 21,721 shares of the company’s stock. This transaction is valued at a significant $4,185,636.
Recent Updates on JNJ stock
Johnson & Johnson reported strong Q3 2025 financial results, with a 6.8% increase in sales to $24 billion and a 15.7% rise in adjusted EPS to $2.80. The company raised its full-year sales outlook, driven by growth in its innovative medicine and MedTech segments, and successful new product launches such as INLEXZO and CARVICTI. Despite challenges like STELARA’s loss of exclusivity and increased tax rates, J&J’s strategic focus on high-impact therapeutic areas and a strong product pipeline support a positive growth outlook. Analysts have upgraded the stock, citing reduced risks from pharmaceutical tariffs and pricing, and confidence in J&J’s ability to navigate the STELARA exclusivity loss.
Spark’s Take on JNJ Stock
According to Spark, TipRanks’ AI Analyst, JNJ is a Outperform.
Johnson & Johnson’s strong financial performance and positive earnings call are the most significant factors driving the score. The technical analysis indicates potential short-term overbought conditions, while the valuation suggests the stock is fairly priced. Overall, the company is well-positioned for continued success, with robust growth prospects in its key segments.
To see Spark’s full report on JNJ stock, click here.
More about Johnson & Johnson
YTD Price Performance: 36.82%
Average Trading Volume: 8,527,257
Technical Sentiment Signal: Buy
Current Market Cap: $465.3B